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State-of-the Art Lecture 1
Friday, July 15, 2011, 08:30 09:00
Meeting Room 309
SOTA1 Hospital Setting: Infection control in the
resistance era
W.-H. Seto*. WHO Collaborating Centre for Infection
Control, Hong Kong S.A.R.
In the hospital, for infection control, it is generally
recognized that it is easier to prevent the spread of
Gram-negative organisms as compared to the Gram positive
bacteria. A summary of the study by Lemmen et al,
JHI 2004:56:191 197 and data from Queen Mary Hospital
Hong Kong will be presented to support the concept. The
MDR Gram-negative organisms are now the focus of global
attention. A brief review of the different types and their
epidemiology in Asia will be presented. A two-tier system
for infection control of MDROs is generally recommended
as also by the CDC of USA. The system will be described.
In the second tier of preventive measures, the particular
measures must be selected based on the organism. In
terms of the newer Gram-negative MDROs, this can be
difﬁcult because the epidemiology of the organisms is still
not entirely clear. Furthermore the effectiveness of the
different microbiology methods such as for screening and
surveillance is not well deﬁned. Nevertheless an attempt
will be made to present the best possible strategies for
various Gram-negative organisms in the present context.
Concurrent Session 1: Hepatitis C Discovering
Genomics
Friday, July 15, 2011, 09:15 10:45
Meeting Room 310
CS1.1 HCV genotypes in hepatitis C patients and their
clinical signiﬁcances
J. Cheng*. Capital University Afﬁliated Beijing Ditan
Hospital, China
Abstract not available
CS1.2 Hepatitis C pharmacogenetics
G. Ahlenstiel *. Storr Liver Unit, Westmead Millennium
Institute, Westmead Hospital, University of Sydney,
Westmead, Australia
Traditionally, the candidate gene approach has been the
standard pharmacogenetic method to identify genetic
polymorphisms relevant for treatment response in human
disease. In 2009 this changed forever, when four
independent groups employed genome wide association
studies (GWAS) to examine the response to interferon-
alpha and ribavirin treatment of chronic hepatitis C virus
(HCV) genotype 1 infection. Importantly, all four studies
consistently identiﬁed polymorphisms in the interleukin 28B
(IL28B) gene, a lambda interferon, as a major determinant
of treatment outcomes. This represented a breakthrough for
our understanding of the pathogenesis of HCV infection and
in drug response for chronic hepatitis C. The studies have
identiﬁed IL28B as a pivotal molecule in these contexts and
explain to some degree the differences between ethnic
groups in treatment responses and the mechanisms for
spontaneous HCV clearance. More recent studies have
addressed the role of IL28B polymorphisms in the natural
history of HCV infection as well as in the context of HCV
genotype 2 and 3 disease and in liver transplantation. This
presentation is an update on the current understanding of
the role of IL28B in HCV infection as well as the role of
GWAS in HCV pharmacogenetics.
CS1.3 Genomic-based treatment paradigms for patients
with chronic hepatitis C infection
A.J. Thompson*. Head of Hepatology Research, St Vincent’s
Hospital, NHMRC Research Fellow, University of Melbourne,
Research Fellow, Victorian Infectious Diseases Reference
Laboratory (VIDRL) & Honorary Visiting Assistant Professor,
Duke University Medical Center, Melbourne, Australia
Abstract not available
CS1.4 Association of IL28B gene variations with
mathematical modeling of viral kinetics in
chronic hepatitis C patients
C.-S. Hsu1,2, D.-S. Chen2,3, J.-H. Kao2,3,4,5. 1Division
of Gastroenterology, Department of Internal Medicine,
Buddhist Tzu Chi General Hospital, Taipei Branch and
School of Medicine, Tzu Chi University, Hualien, Taiwan,
2Graduate Institute of Clinical Medicine, 3Department of
Internal Medicine, 4Department of Medical Research, and
5Hepatitis Research Center, National Taiwan University
College of Medicine and National Taiwan University
Hospital, Taipei, Taiwan
Background and Aims: Asian chronic hepatitis C (CHC)
patients are known to have better virologic responses to
pegylated interferon-based therapy than Western patients.
Although IL28B gene polymorphisms may contribute to
this difference, whether favorable hepatitis C virus (HCV)
kinetics during treatment also plays a role remains
unclear. Therefore, we conducted this study to explore the
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